Abstract
Background: Forty percent of patients with colorectal cancer develop mutations in the K-ras gene.
Objective: Our objective was to evaluate whether the presence of c-K-ras gene mutations is a useful tumor-response marker in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Material and Methods: Thirty seven patients with locally advanced rectal cancer were treated with preoperative chemoradiotherapy. Four to six weeks later, surgery was performed. Specimens were classified according to the UICC-AJC classification. A segment of the tumor was obtained to analyze specific c-K-ras gene mutations. Restriction fragment length polymorphism (RFLP) and single strand confirmation polymorphism (SSCP) techniques were used with a set of probes to detect specific c-K-ras mutations in codons 12, 13, and 61. The 37 patients were divided into Group A (with mutations) and Group B (without mutations).
Results: All 37 patients completed the scheduled treatment. Group A consisted of 12 patients, whose tumors were classified and specific c-K-ras mutations were located as follows: eight in codon 12, two in codon 13, and one in codon 61. Group B consisted of 25 patients. The tumors were classified and there were more early-stage tumors in Group A, whereas in Group B there were more advanced-stage tumors (P 5 .05, respectively). The mean follow-up was 36.2 6 18.3 months. All Group A patients survived, whereas 8 of the 25 patients in Group B died due to progressive metastatic disease. Survival in Group A was 100%, whereas in Group B it was 59% (P 5 .03).
Conclusions: The presence of specific c-K-ras mutations is an indicator of tumor response in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy and surgery. Therefore, responding patients may be more amenable to less radical surgical procedures based on c-K-ras mutations.
This is a preview of subscription content, log in via an institution to check access.
References
Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–767.
Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327:298–303.
Fearon E. K-ras gene mutation as a pathogenic and diagnostic marker in human cancer. J Natl Cancer Inst 1993;85:1978–81.
Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779–827.
McCormick F. Signal transduction. How receptor turns ras on. Nature 1993;63:15–16.
Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044–1048.
Finkelstein SD, Sayegh R, Bakker A, Swalsky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526–532.
Cerottini JP, Caplin S, Saraga E, Givel JC, Benhattar JP. The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 1998;175:198–202.
Senagore AJ, Thebo-Bienner J. A newly identified pattern of k-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer. Surgery 1997;122:765–70.
Morrin M, Kelly M, Barret N, Delaney P. Determination of K-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 1994;35:1627–31.
Norheim-Andersen N, Lovig T, Breivik J, et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 1997;32:62–69.
Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras mutations in colorectal cancer. Gastroenterology 1993;104:57–64.
Kressner U, Bjorheim J, Westring S, et al. Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 1998;34:518–21.
Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980–987.
Gimelius B, Isacsson U, Jung B, Pahlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a doseresponse effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys 1997;37:281–287.
Luna-Pérez P, Trejo-Valdivia B, Labastida S, García S, Rodríguez-Coria DF, Delgado S. Prognostic factors in patients with locally advanced rectal adenocarcinoma treated with preoperative radiotherapy and surgery. World J Surg 1999;23:1069-74.
Sánchez W, Luna-Pérez P, Alvarado I, Labastida S, Herrera L. Modified clearing technique to identify lymph node metastases in post-irradiated surgical specimens from rectal adenocarcinoma. Arch Med Res 1996;27:31–36.
UICC. TNM Classification of Malignant Tumours. Berlin: Springer-Verlag; 1987.
Hermanek KP, Wiebelt H, Staimer DD, Riedl S. The German Study Group on Colorectal Carcinoma (SGCRC). Prognostic factors of rectum carcinoma: experience of the German Multicentre Study SGCRC. Tumori 1995;81(Suppl):60–64.
McLeod RS. Symposium on rectal cancer: 2 local recurrences after surgery for rectal cancer. Can J Surg 1997;40:353–357.
Luna-Pérez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 1998;5:203–208.
Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F, Wittekind CH. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998;41:585–591.
Minamoto T, Yamashita N, Ochiai A, et al. Mutant K-ras in apparently normal mucosa of colorectal Cancer patients. Cancer 1995;75:1520–1526.
Yamashita N, Minamoto T, Ochiai A, et al. Frequent and characteristic K-ras activation in aberrant crypt foci of colon: is there preference among K-ras mutants for malignant progression? Cancer 1975;75:1527–1533.
Pretlow TP, Brasitus TA, Fulton NC, et al. K-ras mutations in putative preneoplastic lesions in the human colon. J Natl Cancer Inst 1993;85:2004–2007.
Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–2.
Losi L, Benhattar J, Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992;28A:1115–1120.
Wadler S, Bajaj R, Neuberg D, Agarwal V, Haynes H, Benson AB. Prognostic implications of c-Ki-ras mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the Eastern Cooperative Oncology Group. Cancer J Sci Am 1997;3:284–288.
Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: is there a survival difference? Meta-analysis of the published literature. Cancer 1996;78:1639–16345.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luna-Pérez, P., Segura, J., Alvarado, I. et al. Specific c-K-ras Gene Mutations as a Tumor-Response Marker in Locally Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy. Ann Surg Oncol 7, 727–731 (2000). https://doi.org/10.1007/s10434-000-0727-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0727-0